T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Veralto
VLTO
|
+$1.39B |
| 2 |
Lattice Semiconductor
LSCC
|
+$366M |
| 3 |
Canadian Natural Resources
CNQ
|
+$329M |
| 4 |
TechnipFMC
FTI
|
+$306M |
| 5 |
Tyler Technologies
TYL
|
+$283M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$1.05B |
| 2 |
Texas Instruments
TXN
|
+$639M |
| 3 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$473M |
| 4 |
Equifax
EFX
|
+$465M |
| 5 |
TransUnion
TRU
|
+$408M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.08% |
| 2 | Healthcare | 20.34% |
| 3 | Industrials | 12.93% |
| 4 | Consumer Discretionary | 12.56% |
| 5 | Financials | 12.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Crinetics Pharmaceuticals
CRNX
$8.97B
| $86M | 0.06% |
2,417,493
+776,801
| +47% | +$23.8M |
|
|
EFOR
302
Everforth Inc
EFOR
$1.33B
| $85.6M | 0.06% |
889,908
+503,320
| +130% | +$44M |
|
303
Mueller Water Products
MWA
$4.03B
| $85.2M | 0.06% |
5,916,437
+17,460
| +0.3% | +$231K |
|
304
Arcosa
ACA
$7.13B
| $84.4M | 0.05% |
+1,021,509
| New | +$75M |
|
|
P
305
Everpure Inc
P
$39B
| $84.2M | 0.05% |
2,359,869
+2,182,559
| +1,231% | +$76.5M |
|
|
BFS
306
Saul Centers
BFS
$854M
| $84.1M | 0.05% |
2,141,415
+3,059
| +0.1% | +$112K |
|
307
Dorman Products
DORM
$3.94B
| $83.6M | 0.05% |
1,001,862
+7,294
| +0.7% | +$545K |
|
308
WillScot Mobile Mini Holdings
WSC
$4.06B
| $83.5M | 0.05% |
1,875,623
+1,117,391
| +147% | +$45.2M |
|
|
HAYN
309
DELISTED
Haynes International, Inc.
HAYN
| $83.4M | 0.05% |
1,462,294
-1,360
| -0.1% | -$65.6K |
|
310
Liberty Live Group Series C
LLYVK
$9.91B
| $83.1M | 0.05% |
2,223,732
+72,607
| +3% | +$2.47M |
|
|
PCH
311
DELISTED
PotlatchDeltic
PCH
| $82.8M | 0.05% |
1,686,898
-169,527
| -9% | -$7.76M |
|
312
BILL Holdings
BILL
$4.81B
| $82.8M | 0.05% |
1,014,728
-1,520,862
| -60% | -$125M |
|
|
PR
313
Permian Resources
PR
$17.6B
| $82.6M | 0.05% |
6,075,535
+3,960,055
| +187% | +$54.2M |
|
|
ENV
314
DELISTED
ENVESTNET, INC.
ENV
| $82.1M | 0.05% |
1,657,619
-58,649
| -3% | -$2.4M |
|
315
Orion
OEC
$362M
| $80.9M | 0.05% |
2,916,310
+35,828
| +1% | +$822K |
|
316
Vaxcyte
PCVX
$8.93B
| $78.3M | 0.05% |
1,246,041
+41,413
| +3% | +$2.15M |
|
317
Enpro
NPO
$7.19B
| $78.1M | 0.05% |
498,302
-1,432
| -0.3% | -$185K |
|
318
Shoals Technologies Group
SHLS
$1.4B
| $78M | 0.05% |
5,021,078
| – | – |
|
319
Humana
HUM
$46.2B
| $78M | 0.05% |
170,435
-727,649
| -81% | -$359M |
|
320
Pacific Biosciences
PACB
$351M
| $76.1M | 0.05% |
7,753,781
+338,257
| +5% | +$2.77M |
|
321
Voya Financial
VOYA
$9.1B
| $75.6M | 0.05% |
1,036,219
+70,626
| +7% | +$4.92M |
|
322
Coca-Cola Consolidated
COKE
$12.7B
| $75.4M | 0.05% |
811,640
-1,069,810
| -57% | -$77.5M |
|
323
Kohl's
KSS
$2.17B
| $74.7M | 0.05% |
2,604,855
+9,607
| +0.4% | +$225K |
|
|
CHUY
324
DELISTED
Chuy's Holdings, Inc. Common Stock
CHUY
| $73.7M | 0.05% |
1,928,818
-120,336
| -6% | -$4.21M |
|
325
MoonLake Immunotherapeutics
MLTX
$1.42B
| $73.7M | 0.05% |
1,220,602
+5,879
| +0.5% | +$303K |
|
Similar funds
T. Rowe Price Investment Management's Q4 2023 Portfolio in Review
As of Q4 2023, T. Rowe Price Investment Management held 644 positions worth $154B, up 8.7% from $141B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Investment Management's Q4 2023 filing shows 73 new, 297 increased, 219 reduced and 48 closed positions. Its largest new stake was Veralto: 18,675,505 shares worth $1.54B. The largest sale was Thermo Fisher Scientific, an estimated $1.05B.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 22% a quarter earlier, followed by Healthcare and Industrials.
- T. Rowe Price Investment Management's largest Q4 2023 buy was Veralto: 18,675,505 shares worth $1.54B.
- T. Rowe Price Investment Management added most to Lattice Semiconductor in Q4 2023, an estimated $366M increase.
- T. Rowe Price Investment Management's biggest Q4 2023 reduction was Thermo Fisher Scientific, cutting an estimated $1.05B.
- T. Rowe Price Investment Management fully exited Texas Instruments in Q4 2023, selling an estimated $639M.
- T. Rowe Price Investment Management's ten largest holdings make up 16% of its $154B portfolio in Q4 2023.
- T. Rowe Price Investment Management opened 73 new positions and closed 48 in Q4 2023.
- T. Rowe Price Investment Management's portfolio value rose 8.7% quarter-over-quarter to $154B.
Based on T. Rowe Price Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.